INTRODUCTION
============

Portal vein thrombosis (PVT) refers to venous thrombosis that develops within the extrahepatic portal venous system which can extend to the branches of the intrahepatic portal vein or up to the splenic vein and superior mesenteric vein^\[[@b1-1391-1-11510-1-10-20200131]\]^. PVT can occur either in association with cirrhosis or malignancy of the liver or may present in the absence of liver disease. Few case studies report an association between sepsis and PVT. We report the first case of PVT presenting with pyelonephritis in a type 1 diabetic patient.

CASE DESCRIPTION
================

An 18-year-old Saudi female known to have type I diabetes mellitus, who was on an insulin pump, presented to the emergency department with epigastric abdominal pain of 3 days' duration, which was non-radiating, colicky in nature and associated with attacks of nausea and vomiting of food content. There was no haematemesis.

On examination: a conscious, alert, oriented young female appearing to be in pain, vital signs were stable with a temperature of 37.7°C and a random blood sugar (RBS) level of 179 mg/dl. Abdominal examination revealed a soft and lax abdomen with tenderness in the epigastric area and right renal angle. There were no signs of rigidity or rebound tenderness. Bowel sounds were present. There was no sign of ascites, splenomegaly or hepatomegaly. The insulin pump was functioning and in place. Per rectal examination was normal.

The patient was initially evaluated by the general surgery team, with the impression of appendicitis. Abdominal ultrasound was normal; this was followed by abdominal CT with contrast, which revealed reduced enhancement of the right kidney, likely indicating acute pyelonephritis. In addition, the left portal vein was oedematous, with complete non-visualization of the supply to liver segment 2, in keeping with complete left branch PVT; there was partial visualization of the right portal vein supplying liver segment 8 with surrounding oedema, in keeping with partial non-occlusive right PVT ([Figs. 1](#f1-1391-1-11510-1-10-20200131){ref-type="fig"} and [2](#f2-1391-1-11510-1-10-20200131){ref-type="fig"}.)

Laboratory investigations revealed a complete blood count showing haemoglobin of 10.7 g/dl, platelets of 255,000/mcl, a white blood cell count of 10.2 × 10^3^ cells/mcl, neutrophils 65%. Renal and liver function results were within normal limits, as were amylase and lipase levels. Haemoglobin A1c was 6.4%. The prothrombin time was 14.1 seconds (11.7--14.5), the INR was 1.48 and the activated partial thromboplastin time was 30.9 seconds (24.1--34.7), the ESR was 48 mm/h (0--20) while CRP was 4.2 mg/dl (0.05--0.3).

Urine analysis showed WBCs at 30--50 per high power field microscopy, pH=7, negative nitrite presence, while culture showed more than 10,000 colony forming units (CFU)/ml. A urine pregnancy test was negative.

The serological testing, including work-up for underlying thrombophilia, is shown in [Table 1](#t1-1391-1-11510-1-10-20200131){ref-type="table"}.

Gastrojejunoscopy and colonoscopy findings were normal. Biopsy revealed chronic non-specific inflammation, preservation of villus architecture and no evidence of intraepithelial lymphocytosis or malignancy.

The patient was managed with ciprofloxacin and anticoagulation therapy (enoxaparin) followed by warfarin. She was then discharged on 8 mg of warfarin with a therapeutic INR. The long-term plan was to continue anticoagulation treatment for 6--12 months and follow up in the outpatient clinic with gastroenterology and haematology assessment; the follow-up imaging showed complete resolution of thrombosis ([Fig. 3](#f3-1391-1-11510-1-10-20200131){ref-type="fig"}).

DISCUSSION
==========

Venous thromboembolism is a condition with varying aetiologies, often involving genetic predisposition, acquired or environmental factors^\[[@b2-1391-1-11510-1-10-20200131]\]^. In PVT, there are 3 major aetiologies: malignant thrombosis, chronic liver diseases -- particularly, cirrhosis with portal hypertension -- and non-cirrhotic and non-malignant PVT^\[[@b3-1391-1-11510-1-10-20200131]\]^.

In a retrospective study carried out in 2006 that included 23,796 post-mortem autopsies, the majority of thromboses occurred secondary to malignancy involving the hepatobiliary region^\[[@b4-1391-1-11510-1-10-20200131]\]^. PVT was present in 14.3% of patients with primary hepatic malignancy accompanied by cirrhosis^\[[@b4-1391-1-11510-1-10-20200131]\]^. Almost one-third of patients with PVT had cirrhotic liver disease. Nevertheless, isolated systemic or local factors have been reported to cause PVT, such as suppurative infections occurring in areas where the drainage is ultimately near the portal vein or 1 of its tributaries. Appendicitis and diverticulitis are considered the most attributable causes of septic thrombophlebitis^\[[@b5-1391-1-11510-1-10-20200131]^\].

Pyelonephritis should be suspected when there is a fever ≥37.8°C with at least 3 out of the 5 following criteria present: (1) lower urinary tract symptoms; (2) flank pain; (3) costophrenic angle tenderness; (4) peripheral blood with leucocytosis ≥20,000/mm^3^ or neutrophils ≥65%; (5) urinary analysis with WBCs ≥10 per high power field ^\[[@b6-1391-1-11510-1-10-20200131]\]^. Our patient had 4 out of 5 of these criteria. CT is the initial study suggested by the American College of Radiology in the assessment of pyelonephritis that has complex presentation as in diabetic or immunocompromised patients ^\[[@b7-1391-1-11510-1-10-20200131]\]^. Most of the studies comparing CT and ultrasonography (US) or Doppler US have shown that CT is superior to US in detecting parenchymal abnormalities. Moreover, CT has higher sensitivity than Doppler US (81.0% and 33.3%, respectively)^\[[@b8-1391-1-11510-1-10-20200131]\]^.

Pyelonephritis with renal vein thrombosis (RVT) has been reported in fewer than 10 cases in the literature, to the best of our knowledge ^\[[@b9-1391-1-11510-1-10-20200131]--[@b15-1391-1-11510-1-10-20200131]\]^.

Until now, no cases have linked acute pyelonephritis to PVT; instead, previous cases consider acute pyelonephritis as a cause of local inflammation and sepsis and then, theoretically, it can cause thromboembolism like other factors.

It appears that RVT caused by acute pyelonephritis occurs in the right renal vein 60% of the time. Moreover, 80% of cases were related to *E. coli* and *Klebsiella pneumoniae*^\[[@b9-1391-1-11510-1-10-20200131]--[@b15-1391-1-11510-1-10-20200131]\]^. These agents are Gram-negative endotoxin-releasing bacteria that stimulate thrombosis. The mechanisms by which hypercoagulability is promoted include the prompting of a change in the surface of the endothelium and decreasing the amount of anticoagulants. Tissue factor gene expression is also increased and cell production in the endothelium of the fibrinolytic inhibitor plasminogen activator inhibitor-1 is enhanced ^\[[@b9-1391-1-11510-1-10-20200131]^\].

In our patient, it is likely that local inflammation resulted in sepsis secondary to pyelonephritis.

The clinical presentation differs based on several factors, including: acuity, the degree of occlusion and the presence of malignant or benign PVT. PVT commonly presents with abdominal pain, diarrhoea, rectal bleeding, vomiting, lactic acidosis, splenomegaly, anorexia and fever, and sepsis can be variably present ^\[[@b16-1391-1-11510-1-10-20200131]\]^.

US is usually the investigation modality of choice for PVT. It shows solid, hyperechoic material in a distended portal vein or its tributaries, the presence of collateral vessels or a cavernoma^\[[@b17-1391-1-11510-1-10-20200131]\]^. Colour Doppler imaging can show the absence of flow in part or all of the vasal lumen, with sensitivity and specificity ranging from 66% to 100%^\[[@b17-1391-1-11510-1-10-20200131],[@b18-1391-1-11510-1-10-20200131]\]^. The CT scan usually shows PVT as a hypodense filling defect in the portal vein lumen, with partial or complete occlusion on contrast-enhanced scans^\[[@b19-1391-1-11510-1-10-20200131]\]^. Moreover, CT is useful for the identification of the possible cause of the thrombosis or potential complications ^\[[@b20-1391-1-11510-1-10-20200131]\]^.

The next step after a diagnosis of PVT has been made is to start an extensive investigation of the cause of the thrombosis, which may include local abdominal factors and prothrombotic disorders.

Our patient was extensively assessed for the presence of cirrhosis and local abdominal causes of thrombosis, which were negative. A thrombophilia screen including testing for inherited genetic mutation for a hypercoagulable state was all normal, and no detectable mutations were found. No apparent cause for the thrombosis was recognized except the presence of sepsis.

The aim of the treatment is to reverse or prevent advancement of thrombosis in the portal venous system and to treat complications for established PVT. Early initiation of anticoagulation therapy within 30 days of symptoms manifesting is recommended, as there is no spontaneous recanalization reported except in acute pancreatitis ^\[[@b18-1391-1-11510-1-10-20200131]\]^. Turnes and colleagues found that early anticoagulation therapy could achieve recanalization in 12 out of 27 patients (44%) without cirrhosis and malignancy compared to 0 out of 11 patients who were not given anticoagulation treatment^\[[@b21-1391-1-11510-1-10-20200131]\]^. Recanalization decreased from 69% when anticoagulation therapy was instituted within the first week to 25% when instituted in the second week^\[[@b18-1391-1-11510-1-10-20200131],\ [@b21-1391-1-11510-1-10-20200131]\]^. Early anticoagulation therapy had been initiated in our patient with successful complete revascularization and resolution of thrombosis in subsequent follow-up imaging.

CONCLUSIONS
===========

PVT is an uncommon condition in the absence of liver disease. Few cases report an association between sepsis and PVT. Sepsis can create a predisposed environment for hypercoagulability. Moreover, it may trigger the coagulation cascade for thrombus formation. The management of PVT should be individualized and should weigh the benefits and risks for every patient.
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![CT scan of the abdomen showing intrahepatic periportal thickening and oedema that is more severe at the left liver lobe ducts causing portal vein thrombosis](1391_Fig1){#f1-1391-1-11510-1-10-20200131}

![Axial contrast-enhanced CT scan of the abdomen showing multiple areas of decreased enhancement (low attenuation) in the right kidney, and normal renal arteries and veins. This is suggestive of acute pyelonephritisthrombosis](1391_Fig2){#f2-1391-1-11510-1-10-20200131}

![Follow-up Doppler and colour flow mapping with no sonographic evidence of thrombosis. The portal vein at the porta hepatis and its main right and left branches show normal colour filling](1391_Fig3){#f3-1391-1-11510-1-10-20200131}

###### 

Thrombophilic screening

  *Test*                                  *Value*       *Reference Range*   *Interpretation*
  --------------------------------------- ------------- ------------------- ------------------
  *Anti-gliadin*                          *0.9 CU*      *\<20 CU*           *Negative*
  *Anti-endomysial*                       *\<2.5 CU*    *\<5 CU*            *Negative*
  *Anti-β2-glycoprotein 1 Antibody IgG*   *\<6.4 CU*    *0--20 CU*          *Negative*
  *Anti-β2-glycoprotein 1 Antibody IgM*   *\<1.1 CU*    *0--20 CU*          *Negative*
  *Anticardiolipin antibody IgG*          *15.7 CU*     *0--20 CU*          *Negative*
  *Anticardiolipin antibody IgM*          *1.1 CU*      *0--20 CU*          *Negative*
  *ANA*                                   *80*          *\<40*              *Negative*
  *ANCA*                                  *\<20*        *\<20*              *Negative*
  *Rheumatoid factor*                     *10 IU/ml*    *\<14 IU/ml*        *Negative*
  *IgA*                                   *235 ng/dl*   *61--348 ng/dl*     *Normal*
  *Factor V Leiden (G1691A)*              *-*           *-*                 *Not detected*
  *Factor II (G20210A)*                   *-*           *-*                 *Not detected*
  *JAK2 V617F*                            *-*           *-*                 *Not detected*
  *Antithrombin III mutation*             *93*          *80--120*           *Normal*
  *Protein C*                             *60*          *70--140*           *Normal*
  *Protein S*                             *110*         *65--140*           *Normal*
